# Yellow fever disease severity and endothelial dysfunction are associated with elevated serum levels of viral NS1 protein and syndecan-1

- 3
- 4 Francielle T. G. de Sousa<sup>1,2</sup>, Colin M. Warnes<sup>1</sup>, Erika R. Manuli<sup>2,3</sup>, Arash Ng<sup>4</sup>, Luiz G. F. A. B.
- 5 D'Elia Zanella<sup>5,6</sup>, Yeh-Li Ho<sup>5</sup>, Samhita Bhat<sup>1</sup>, Camila M. Romano<sup>2,3</sup>, P. Robert Beatty<sup>1,4</sup>, Scott B.
- 6 Biering<sup>1</sup>, Esper G. Kallas<sup>5</sup>, Ester C. Sabino<sup>2,5</sup>, Eva Harris<sup>1,4</sup>
- 7
- <sup>8</sup> <sup>1</sup>Division of Infectious Diseases and Vaccinology, School of Public Health, University of
- 9 California, Berkeley, Berkeley, CA, USA
- 10 <sup>2</sup> Departamento de Doenças Infecciosas e Parasitárias, Instituto de Medicina Tropical, Faculdade
- 11 de Medicina da Universidade de São Paulo, São Paulo, SP, 05403000, Brazil
- 12 <sup>3</sup>Laboratório de Investigação Médica, Hospital das Clínicas da Faculdade de Medicina da
- 13 Universidade de São Paulo (HCFMUSP), São Paulo-SP, 05403000, Brazil
- <sup>4</sup>Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA,
- 15 USA
- <sup>5</sup>Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP),
- 17 São Paulo-SP, 05403000, Brazil
- 18 <sup>6</sup>Instituto de Infectologia Emílio Ribas, São Paulo-SP, 01246-900, Brazil
- 19
- 20 Correspondence to Ester C. Sabino (<u>sabinoec@usp.br</u>) and Eva Harris (eharris@berkeley.edu)

## 22 Abstract

23 Yellow fever virus (YFV) infections can cause severe disease manifestations, including hepatic 24 injury, endothelial damage, coagulopathy, hemorrhage, systemic organ failure, and shock, and are 25 associated with high mortality in humans. While nonstructural protein 1 (NS1) of the related 26 dengue virus is implicated in contributing to vascular leak, little is known about the role of YFV 27 NS1 in severe YF and mechanisms of vascular dysfunction in YFV infections. Here, using serum 28 samples from qRT-PCR-confirmed YF patients with severe (n=39) or non-severe (n=18) disease 29 in a well-defined hospital cohort in Brazil, plus samples from healthy uninfected controls (n=11), 30 we investigated factors associated with disease severity. We developed a quantitative YFV NS1 31 capture ELISA and found significantly increased levels of NS1, as well as syndecan-1, a marker 32 of vascular leak, in serum from severe YF as compared to non-severe YF or control groups. We 33 also showed that hyperpermeability of endothelial cell monolayers treated with serum from severe 34 YF patients was significantly higher compared to non-severe YF and control groups as measured 35 by transendothelial electrical resistance (TEER). Further, we demonstrated that YFV NS1 induces 36 shedding of syndecan-1 from the surface of human endothelial cells. Notably, YFV NS1 serum 37 levels significantly correlated with syndecan-1 serum levels and TEER values. Syndecan-1 levels 38 also significantly correlated with clinical laboratory parameters of disease severity, viral load, 39 hospitalization, and death. In summary, this study points to a role for secreted NS1 in YF disease 40 severity and provides evidence for endothelial dysfunction as a mechanism of YF pathogenesis in 41 humans.

42

43 Keywords: yellow fever, pathogenesis, endothelial dysfunction, NS1, syndecan-1

## 45 Significance

- 46 Yellow fever virus (YFV) infections cause a major global disease burden, and as such it is critical
- 47 to identify clinical correlates of disease severity. Using clinical samples from our hospital cohort
- 48 in Brazil, we show that YF disease severity is associated with increased serum levels of the viral
- 49 nonstructural protein 1 (NS1) and soluble syndecan-1, a marker of vascular leak. This study
- 50 extends the role of YFV NS1 in triggering endothelial dysfunction to human YF patients,
- 51 previously demonstrated *in vitro* and in mouse models. Further, we developed a YFV NS1-capture
- 52 ELISA that serves as a proof-of-concept for low-cost NS1-based diagnosis/prognosis tools for YF.
- 53 Together, our data shows that YFV NS1 and endothelial dysfunction are important components of
- 54 YF pathogenesis.

#### 56 Introduction

57 Yellow fever virus (YFV) is an arbovirus endemic to tropical areas of Central and South America 58 and sub-Saharan Africa and the causative agent of yellow fever (YF) disease. YF is considered a 59 reemerging disease, with increasing infections over the past 20 years, exemplified by epidemics in 60 2015 and 2016 in Angola and the Democratic Republic of Congo and in 2016-2019 in Brazil (1, 61 2). The clinical spectrum of YF in humans ranges from asymptomatic infection to mild illness to 62 severe disease. Manifestations of severe disease include vasculopathy and organ impairment of the 63 liver, kidneys, lungs, intestine, and brain, resulting in high reported case fatality rates (20-60%) 64 (2).

65

YFV is a member of the *Flavivirus* genus of the *Flaviviridae* family, with a positive-sense RNA 66 67 genome of approximately 11 kb that encodes three structural and seven nonstructural proteins (3). 68 The Flavivirus nonstructural protein 1 (NS1) is secreted by infected cells and has been used as a 69 serological diagnostic marker for dengue (4). Further, dengue virus (DENV) NS1 levels have been 70 correlated with disease severity (5-7). We have recently shown that *Flavivirus* NS1 can directly 71 cause vascular leak *in vitro* and in animal models in a tissue-specific manner that reflects the viral 72 disease tropism (8, 9). Mechanisms of NS1-induced endothelial dysfunction include disruption of 73 key barriers of endothelial integrity such as the glycocalyx (8) and intercellular junctional 74 complexes (9, 10). Further, studies have demonstrated that soluble NS1, independently from the 75 virus, can act on endothelial cells to facilitate viral dissemination and pathology (11, 12). In 76 addition, DENV NS1 has been shown to increase circulating levels of glycocalyx components 77 including sialic and hyaluronic acid, heparan sulfate, and syndecan-1 (SDC-1) in vitro, in animal 78 models, and in clinical samples (8, 13–18). However, while YFV NS1 can trigger endothelial 79 dysfunction in vitro and in animal models (8), a direct correlation of NS1 levels with severe YF 80 disease in humans has not been demonstrated.

81

SDC-1, also known as CD138, is an extracellular matrix receptor and a member of the transmembrane heparan sulfate proteoglycan family. SDC-1 is involved in many cellular functions, including cell-cell and cell-matrix adhesion, and is highly expressed by epithelial, endothelial, and hematopoietic cells (19, 20). As a part of normal cell surface proteoglycan turnover, the ectodomain of SDC-1 is constitutively shed from the cell surface via proteolytic cleavage by

87 metalloproteinases (21). Increased levels of soluble syndecan-1 (sSDC-1) have been detected in 88 response to injury or infection, and sSDC-1 is often utilized as a marker for glycocalyx disruption. 89 Therefore, sSDC-1 has been identified as a potential prognostic factor in cancer and systemic 90 inflammatory and autoimmune diseases (19, 20, 22). In addition, sSDC-1 has been associated with 91 severe manifestations of SARS-CoV-2 infection (23, 24), and elevated levels of sSDC-1 were 92 found in patients with severe dengue due to the destruction of the glycocalyx associated with 93 vascular leak (16, 25). Nonetheless, to date, a link between YF disease severity and glycocalyx 94 disruption or increased serum levels of sSDC-1 has not yet been demonstrated.

95

96 In this study, we use a well-defined cohort of patients with YFV infection to examine the 97 relationship between levels of YFV NS1, sSDC-1, and severe disease manifestations. We found 98 significantly higher levels of YFV NS1 and sSDC-1 in sera of severe YF patients as compared to 99 non-severe YF and control groups. YFV NS1 and sSDC-1 serum levels correlated with each other 100 and with clinical laboratory signs of severe YF disease. We also found that treatment of endothelial 101 monolayers with serum from individuals with severe YF induced significantly higher levels of 102 endothelial permeability as compared to the non-severe YF and control groups. Further, YFV NS1 103 treatment of endothelial cells induced syndecan shedding, as observed by immunofluorescence 104 assay. Together, these results provide evidence for a role of NS1 in YF disease and for endothelial 105 glycocalyx disruption as a pathogenic mechanism in YFV infections in humans.

106

#### 107 **Results**

#### 108 Characteristics of study participants

109 In this study, we analyzed serum samples from individuals with suspected YF collected at the time 110 of hospital admission during an observational cohort study initiated during the 2018 YF epidemic 111 in São Paulo, Brazil, as previously described (2), and continued through the subsequent epidemic 112 in 2019. Demographic characteristics, clinical manifestations, and laboratory data of study 113 participants with RT-PCR-confirmed YF cases as well as healthy controls are provided in Table 1. 114 We used the laboratory criteria (viral load, neutrophil count, aspartate transaminase [AST], 115 creatinine, and indirect bilirubin [IB]) previously determined to predict mortality in YF patients 116 from the same cohort (2), or death, to define severe cases. Table 1 shows that in addition to these 117 criteria, severe YF cases also displayed significantly higher levels of alanine aminotransferase

- 118 (ALT), total bilirubin (TB), and direct bilirubin (DB), as well as increased prothrombin time
- 119 (PT/INR) and activated partial thromboplastin time (aPTT), when compared to the non-severe
- 120 group. The majority of YF-positive study participants were male agriculture or forestry workers.
- 121

## 122 Development of a quantitative YFV NS1 capture ELISA for clinical samples

123 While YFV NS1 has been previously implicated as a direct trigger of endothelial dysfunction and 124 vascular leak in vitro and in mouse models (8), the contribution of YFV NS1 to endothelial 125 dysfunction in humans is unknown. To measure YFV NS1 levels in the serum of infected patients, 126 we established a quantitative YFV NS1 capture ELISA using an in-house-produced mouse anti-YFV-NS1 monoclonal antibody (mAb). After testing different mAbs, YFJ19 (IgG1) used as the 127 128 capture mAb and biotinylated YFJ19 as the detection mAb was determined to be the optimal 129 combination, displaying the highest signal and specificity for YFV NS1 (Supplementary Fig. 1). 130 Standard curves were generated via ELISA with recombinant YFV NS1 concentrations (0.24-2000 131 ng/mL) versus absorbance values (Fig. 1A), with no significant changes observed when human 132 serum (1:10) was added (Fig. 1B), indicating that the assay could be performed with clinical 133 samples. The analytic detection range was 2 to 500 ng/mL. YFJ19, as well as 2B7, a pan-flavivirus 134 anti-NS1 mAb, was tested across a panel of 12 flavivirus NS1 proteins using both direct ELISA 135 and Western blot methods. Results show that YFJ19, in contrast to 2B7, was specific to YFV NS1 136 (Fig. 1C, D, E). This specificity is important for assays detecting flavivirus NS1, especially 137 because different flaviviruses can co-circulate in endemic areas such as Brazil.

138

#### 139 NS1 serum levels are significantly increased in severe YF

Using our in-house ELISA, we found that YFV NS1 levels were significantly higher in the severe YF group (mean=118.8 ng/mL) compared to the non-severe group (mean=29.5 ng/mL) and to the control group (no NS1 detected) (Fig. 2A). We also observed trending higher levels of YFV NS1 when comparing the deceased to the surviving group (Fig. 2B). YFV NS1 serum levels were observed to be highest between 5-13 days post-symptoms onset (Fig. 2C).

145

## 146 Serum levels of syndecan-1 correlate with disease severity in YF patients

147 Because sSDC-1 is a biomarker for endothelial injury in multiple diseases, we quantified sSDC-1

148 in the serum samples of our cohort. We found significantly increased sSDC-1 levels in severe vs. 149 non-severe YF cases and significantly higher levels in both non-severe and severe YF groups when 150 compared to healthy controls (Fig. 3A). Importantly, sSDC-1 levels were also significantly higher 151 in individuals who succumbed compared to those who survived (Fig. 3B). These findings indicate 152 that endothelial dysfunction is associated with disease severity in YFV-infected patients and that 153 sSDC-1 can be used as a biomarker of YF disease severity. Similar to YFV NS1, sSDC-1 serum 154 levels were highest 4-13 days after symptom onset (Fig. 3C). We also found that, as expected, 155 sSDC-1 levels when compared to the same healthy controls as above were significantly increased 156 in serum samples from dengue patients with diagnosed vascular leak obtained in our previous 157 study (26) (Fig. 3D).

158

## 159 Sera from patients acutely infected with YFV induce endothelial dysfunction *in vitro*,

## 160 correlating with disease severity

161 To evaluate the capacity of serum from YF patients to mediate endothelial hyperpermeability, we 162 evaluated the transendothelial electrical resistance (TEER) of human endothelial cells cultured in 163 Transwell inserts and treated with sera from the different groups. We found that mean relative 164 TEER values of severe and non-severe YF groups were reduced in comparison to medium-only or 165 control groups, indicating that serum components were capable of inducing varying degrees of 166 endothelial hyperpermeability according to disease severity (Fig. 4A). Comparing the area under 167 the curve (AUC) of TEER nadirs, the severe YF group displayed significantly greater values when 168 compared to both non-severe YF and control groups (Fig. 4B). Similarly, recombinant YFV NS1, 169 used as positive control, induced endothelial dysfunction resulting in reduction of relative TEER 170 values (Fig. 4A, B). The TEER curves for each sample are shown in Supplementary Fig. 2.

171

## 172 YFV NS1 induces sSDC-1 shedding in endothelial cells

To evaluate the capacity of YFV NS1 to serve as a direct trigger of endothelial dysfunction, we measured the effect of NS1 on SDC-1 levels on a monolayer of human endothelial cells. Consistent with our observed correlation between YFV NS1 and sSDC-1 in clinical samples, we found that YFV NS1 treatment of endothelial cells resulted in a significant reduction of cell surface-bound SDC-1 relative to medium only control (Fig. 4C, D, E). These data support a direct role for YFV

178 NS1 as a contributing factor to endothelial dysfunction in YF patients.

179

## 180 TEER, sSDC-1, and YFV NS1 serum levels correlate with parameters of severe YF

181 We next performed a correlation matrix analysis of patient data and results regarding TEER, sSDC-182 1 and YFV NS1 levels (Fig. 5A, with significant [p<0.05, r>0.35] correlations indicated with 183 asterisks). Importantly, we found that YFV NS1 levels correlated with sSDC-1 levels, TEER 184 values, neutrophil count, hematocrit (Ht), and IB (Fig. 5A, B, C). Further, sSDC-1 levels correlated 185 significantly with YFV NS1, TEER values, gender, hospitalization, viral load, parameters of liver 186 impairment (AST, ALT, creatinine, TB, DB, and IB), kidney dysfunction (creatinine), 187 coagulopathy (fibrinogen, PT/INR, aPTT), and death (Fig. 5A, D). TEER values correlated with 188 YFV NS1, sSDC-1, gender, creatinine, TB, DB, and IB (Fig. 5A, C, D). Thus, these findings show 189 that TEER values and levels of YFV NS1 and sSDC-1 correlated with each other and with clinical 190 laboratory parameters of disease severity, suggesting a potential link between YFV NS1 and 191 endothelial dysfunction, resulting in increased shedding of sSDC1.

192

#### 193 **Discussion**

194 Our findings in this study indicate that in humans, YFV NS1 may directly target the endothelium, 195 triggering breakdown of the glycocalyx via enzymatic activation, consistent with our previous 196 report using in vitro and in vivo models (8). Serum levels of both NS1 and sSDC-1 were correlated 197 with several clinical laboratory parameters associated with YF disease, providing evidence that 198 YFV NS1 and sSDC-1 may be linked to severe YF disease manifestations. When placing human 199 endothelial cells in contact with sera from the different groups, we observed a significant increase 200 in permeability with the severe as compared to non-severe and healthy control groups. We also 201 confirmed in vitro by IFA that YFV NS1 induces shedding of sSDC-1 from human endothelial 202 cells. Our results highlight the secretion of YFV NS1 from infected cells and endothelial 203 glycocalyx degradation, as measured by sSDC-1 shedding, as prominent characteristics of YF 204 pathogenesis in humans and suggest that levels of NS1 and/or levels of sSDC-1 may help assess 205 risk of developing severe illness.

206

207 Flavivirus NS1 is an important virulence factor in facilitating flavivirus pathogenesis by triggering

208 enzymatic disruption of the glycocalyx as well as mediating the breakdown of intercellular 209 junctional complexes of endothelial cells, both pathways contributing to tissue-specific vascular 210 leak (8, 9, 27). We have previously shown that YFV NS1 treatment induces significant 211 hyperpermeability in human endothelial cells and in mice (8). Our data here shows that severe YF 212 cases displayed higher levels of YFV NS1 as early as 5 days post-disease onset, supporting the 213 concept that production of NS1 by YFV-infected cells may contribute to YF disease. Thus, 214 measuring the serum levels NS1 could potentially provide a clinical diagnostic/prognostic marker 215 for YF.

216

SDC-1 is a heparan sulfate proteoglycan expressed on endothelial cells and an established marker of inflammatory disease and glycocalyx damage (28). Shedding of endothelial glycocalyx components, such as sSDC-1, is a known result of endothelial dysfunction, and increased serum levels of sSDC-1 have been confirmed in patients with diseases such as dengue (16, 25, 29, 30), COVID-19 (24), septic shock (31), and cancer (32, 33). Here, we show that higher levels of sSDC-1 correlate with severe YF; thus, sSDC-1 may also serve as a biomarker for severe YF disease.

224 YF is a systemic disease, but the pathology is primarily targeted to the liver. A recent study 225 highlighted endothelial activation, showing immunohistochemical analysis of endothelial tissues 226 in the hepatic parenchyma of YF-positive subjects, with increased expression of adhesion 227 molecules (34). This study suggested that YFV induces endothelial activation, stimulating the 228 rolling, recruitment, and migration of immune cells that contribute to inflammatory processes in 229 the liver of fatal cases. Our current results highlight secretion of YFV NS1 into the bloodstream, 230 where it presumably interacts with the endothelium, activating glycocalyx degradation and SDC-231 1 shedding that leads to endothelial hyperpermeability and possibly contributing to the hepatic and 232 systemic inflammatory response.

233

In a previous study by Kallas et al. (2019), older age, male sex, higher leukocyte and neutrophil counts (>4000 cells/ mL), AST, bilirubin, creatinine, and viral load (>5.1 log10 copies/mL), as well as prolonged prothrombin time, were associated with increased mortality in patients with YF (2). Thus, we used these parameters to classify severe cases of YF in our current study, which utilized samples obtained from the same cohort. In a more recent study, hyperimmune activation

and perturbation of the gut microbiome related to heightened levels of microbial translocation were also found to be associated with severe outcome in these patients (35). Moreover, coagulopathy in YF patients from the same cohort and in YFV-infected macaques was not only associated with defects in clotting factor synthesis due to hepatocyte infection, but also with coagulation factor consumption, shown by increased concentrations of plasma D-dimer (36).

244

245 Antigenic cross-reactivity during diagnosis of flaviviral diseases is a major challenge, particularly 246 in endemic settings where multiple flaviviruses co-circulate (37). Therefore, assays measuring 247 NS1 in sera must be highly specific to avoid incorrect diagnosis. The presence of NS1 is widely 248 used as an early diagnostic marker for flavivirus infections, especially dengue (38). We produced 249 and tested multiple novel anti-YFV NS1 mAbs when developing our YFV NS1 capture ELISA, 250 aiming for minimal cross-reactivity to other flavivirus NS1 proteins while maintaining the highest 251 sensitivity possible. Because our newly developed YFV NS1 ELISA is highly specific and can 252 detect low concentrations of NS1 in supernatants or sera, it could be used in research and clinical 253 settings, including differential diagnosis of flaviviruses at lower cost compared to molecular 254 assays, with additional potential for prognosis.

255

Taken together, our study identifies YFV NS1 and sSDC-1 as correlates of YF disease severity and endothelial dysfunction. Our work suggests that endothelial dysfunction is a major clinical manifestation of human YF, as in dengue, and that circulating NS1 may contribute to this pathogenesis, as has been observed *in vitro* and in murine models. Further, our development of a highly specific YFV NS1 capture ELISA can serve as a proof-of-concept for the development of low-cost NS1-based diagnostics of YF and perhaps be used to predict YF disease progression in humans.

263

#### 264 Methods

#### 265 Study participants

This study utilized samples from patients with YF cases confirmed by detection of YFV genomic RNA in plasma and/or autopsy tissues by qRT-PCR, as previously described (2). Patients were enrolled at the Hospital das Clínicas, School of Medicine, University of São Paulo, Brazil, during an observational cohort study from January 2018 through February 2019 (2). Blood samples were

270 collected at the time of admission after informed consent and before any treatment intervention or 271 diagnostic procedure. Blood samples were used for clinical laboratory tests including 272 determination of viral load; leukocyte and platelet counts; levels of hemoglobin, AST, ALT, 273 creatinine, fibrinogen, and total, direct, and indirect bilirubin; and coagulation time. Cases were 274 classified in three groups, as follows: i) non-severe (N=18): individuals who presented viral load 275 <10<sup>5</sup> genomic copies/mL, neutrophil count <4000/mL, AST <3500 U/L, creatinine <2.36 mg/mL, 276 and IB <0.64 mg/dL and who recovered; ii) severe (N=39): individuals who presented one or more of the following criteria: viral load  $\geq 10^5$  genomic copies/mL; neutrophil count  $\geq 4000$ /mL, AST 277 278  $\geq$ 3500 U/L, creatinine  $\geq$ 2.36 mg/mL, IB  $\geq$ 0.64 mg/dL, and/or death; iii) control (N=11): healthy 279 individuals. The study was approved by the Institutional Review Board of the University of São 280 Paulo (approval # CAAE: 59542216.3.1001.0068).

281

## 282 Hybridoma production and ELISA and Western blot analysis

283 BALB/c mice were immunized intraperitoneally three times with 10 µg of recombinant YFV NS1 284 (Strain 17D, Native Antigen) diluted 1:1 in Sigma adjuvant system, and a fourth immunization 285 with YFV NS1 alone. Splenocytes were fused with A1 myeloma cells, and hybridomas were 286 selected on hypoxanthine-aminopterin-thymidine medium and screened with a YFV NS1 antigen-287 coat ELISA. In brief, Nunc MaxiSorp ELISA plates (Thermo Scientific) were coated overnight 288 with 0.5 µg/mL of YFV NS1 in PBS and blocked the next day for 1 hour (h) using PBS containing 289 5% nonfat dry milk, washed twice with PBS, and incubated with hybridoma supernatant for 1h at 290 room temperature. Plates were washed 3X with PBS-Tween20 0.01% (PBS-T) and 2X with PBS, 291 and HRP-conjugated secondary antibody diluted in PBS-BSA 1% was added for 1h. After washing 292 with PBS-T, 3,3',5,5'-Tetramethylbenzidine (TMB) liquid substrate (Sigma) was added and left to 293 develop for 10 minutes. Plates were read at OD<sub>450</sub> nm using a BioTek/Agilent microplate reader. 294 The mAbs with the highest OD value and shortest growth doubling time were selected for 295 expansion and purification. Cells from ELISA-positive wells were sub-cloned and expanded 296 before being tested by ELISA for YFV specificity using 12 recombinant flavivirus NS1 proteins 297 purchased from Native Antigen Company: YFV; dengue virus serotypes 1 (DENV1), 2 (DENV2), 298 3 (DENV2), and 4 (DENV4); Saint Louis encephalitis virus (SLEV); West Nile virus (WNV); 299 Zika virus (ZIKV); Wesselsbron virus (WBV); Usutu virus (USUV); Japanese encephalitis virus 300 (JEV); and tick-borne encephalitis virus (TBEV) (31).

301

302 The YFJ19 mAb was tested by Western blot for specificity to YFV NS1. The same 12 recombinant 303 flavivirus NS1 proteins used above were separated on a 10% polyacrylamide gel and transferred 304 onto nitrocellulose membranes. Membranes were incubated overnight with 7 mL of hybridoma 305 supernatant or 3.5 µL of mouse anti-His mAb (Abcam) as a control in PBS-T containing 5% nonfat 306 dry milk. After antibody incubation, membranes were washed 4X with PBS-T and then probed 307 with anti-mouse secondary antibodies conjugated to horseradish peroxidase (HRP; Biolegend) for 308 1h. Membranes were then washed 4X with PBS-T, developed using ECL reagents, imaged on a 309 ChemiDoc system, and analyzed using Image Lab software (Bio-Rad).

310

## 311 **mAb purification**

Hybridoma supernatant in batches of 400 mL were filtered using a 0.22 µm pore size bottle-top 312 313 vacuum filter (Corning) to remove cell debris. Buffers were developed based on the manufacturer's 314 recommendations (Cytiva Protein G Sepharose 4 Affinity Chromatography Handbook). 315 Supernatant was diluted 1:1 with binding buffer (20 mM H<sub>2</sub>NaO<sub>4</sub>P·H<sub>2</sub>O, pH 7.0). Protein G resin 316 (2.5 mL, Cytiva Protein G SepharoseTM 4 Fast Flow) was added to a 1.0 x 10 cm Econo-Column 317 (Bio-Rad) and washed twice with 10 mL of binding buffer. Supernatant/binding buffer solution 318 was added to a Econo-Column Reservoir (Bio-Rad) attached to the Econo-Column and allowed to 319 gravity flow through the resin. After flow-through was collected, the resin was washed twice with 320 10 mL of binding buffer to remove supernatant. To elute the bound mAbs, 6 mL of elution buffer 321 (0.1 M glycine buffer, pH 2.5-3.0) was added to the column. Elution fractions were collected in 1-322 mL fractions and diluted 1:10 with neutralizing buffer (1 M TrisHCl, pH 9.0). mAb concentration 323 was calculated using a Nanodrop spectrophotometer, and the top yields were selected and pooled. 324 Purified mAbs were dialyzed using a Slide-A-Lyzer 10K (Fisher) over 48h at 4°C with two 325 separate exchanges of PBS buffer.

326

## 327 YFV NS1 capture ELISA

ELISA plates were coated with 5  $\mu$ g/mL of capture mAb in 50  $\mu$ L PBS/well and incubated at 4°C overnight. The next day, plates were washed once with PBS and blocked with PBS-BSA 3% (100  $\mu$ L) and incubated for 1h at room temperature. The plate was then washed twice with PBS-T, and the serum or recombinant NS1 was diluted in PBS-BSA 1% (50  $\mu$ L) before being added to the

332 plate and incubated for 1h at room temperature. Plates were washed 4X with PBS-T, and the 333 biotinylated detecting mAb (Pierce Antibody Biotinylation Kit for IP, ThermoFisher) was diluted 334 in PBS-BSA 1% (50 µL) and added to the plate to incubate for 1h at room temperature. The plate 335 was then washed 4X with PBS-T. HRP-streptavidin (Jackson Immuno) diluted in PBS-BSA (50 336 µL) was then added to the plate and incubated at room temperature for 1h. After incubation, the 337 plate was washed 4X with PBS-T and 1X with PBS. The plate was then developed with TMB 338 substrate (100 µL; Sigma) for ~15 minutes. The enzymatic reaction was interrupted using 2N 339  $H_2SO_4$ , and the plate was read at  $OD_{450}$  nm. The concentrations of NS1 in sera were interpolated 340 using a standard curve of recombinant NS1 ranging from 1 to 1000 ng/mL; the limit of detection 341 for this assay was 2 ng/mL.

342

#### 343 Determination of sSDC-1 levels in human serum

344 The amount of sSDC-1 in serum was determined using the human SDC-1 DuoSet ELISA Kit 345 (DY2780, R&D Systems). Briefly, 96-well ELISA microplates were coated with 80 ng/well of 346 goat anti-human SDC-1 capture antibody overnight at room temperature. After washing and 347 blocking with 1% bovine serum albumin (BSA), plates were incubated with samples diluted 1:25 348 or recombinant human SDC-1 standards for 2h. After washing, plates were incubated with 5 349 ng/well of biotinylated goat anti-human SDC-1 detection antibody. After 2h, HRP-streptavidin was 350 added for signal detection with TMB substrate. The OD<sub>450</sub> with a correction at OD<sub>550</sub> was 351 determined using a microplate reader. sSDC-1 levels were determined by interpolation analysis of 352 standard curves with four-parameter logistic regression.

353

## 354 Evaluation of endothelial barrier function *in vitro*

355 To evaluate the putative effects of serum from acutely YFV-infected patients on endothelial barrier 356 function, we used the TEER assay as described previously (26, 27). In brief, human umbilical vein 357 endothelial cells, kindly donated by Dr. Miriam Fonseca-Alaniz (Instituto do Coração, InCor, 358 University of São Paulo, Brazil) were seeded ( $6x10^4$  cells/well) in Transwell polycarbonate 359 membrane inserts (0.4 µm pore, 6.5 mm diameter; Corning Inc.) in endothelial cell growth basal 360 medium 2 supplemented with an Endothelial Cell Growth Medium-2 (EGM-2TM) supplemental 361 bullet kit (Lonza). After 72h of incubation at 37°C and 5% CO<sub>2</sub>, cells were treated with human sera (10% final vol/vol concentration) obtained from YFV-positive severe and non-severe patients 362

363 or YFV-negative blood donors (healthy controls). TEER values, expressed in Ohms ( $\Omega$ ), were 364 collected at sequential 2-h time-points 2-10h following treatments using an Epithelial Volt Ohm 365 Meter (EVOM) with a "chopstick" electrode (World Precision Instruments). Resistance of inserts 366 with no cells (blank) and inserts with cells (untreated) containing medium alone, were used to 367 calculate relative TEER as a ratio of the corrected resistance values as ( $\Omega$  experimental condition 368 -  $\Omega$  blank)/( $\Omega$  untreated -  $\Omega$  blank). Recombinant YFV NS1 (Native Antigen Co.) at 10 µg/mL was 369 used as positive control.

370

## 371 Measurement of SDC-1 levels on the surface of human endothelial cells by 372 immunofluorescence assay (IFA)

373 HPMEC (1x10<sup>5</sup> cells) were seeded on gelatin-coated coverslips and allowed to grow until full 374 confluency was attained (approximately 3 days). On the day of the experiment, cells were treated 375 or not with 10 µg/mL of YFV NS1 protein and incubated for 3h at 37°C. After incubation, cells 376 were washed, fixed with 4% paraformaldehyde (PFA), and stained overnight with 2 ug/mL of the 377 rabbit anti-SDC-1 IgG antibody (Abcam, ab188861). After washing, secondary staining was 378 performed by adding 2 ug/mL of donkey anti-rabbit IgG conjugated to Alexa Fluor 647 (Abcam, 379 ab150075) for 4h. Nuclei were stained using Hoechst (ImmunoChemistry Technologies). Mounted 380 slides were imaged on a Zeiss LSM 710 Axio Observer fluorescence microscope (CRL Molecular 381 Imaging Center, UC Berkeley). Images acquired using the Zen 2010 software (Zeiss, Jena, 382 Germany) were processed and analyzed with ImageJ software (39). Mean fluorescence intensity 383 (MFI) values for SDC-1 staining were obtained from individual RGB-grayscale-transformed 384 images (n = 3).

385

#### 386 Statistics

ELISA values were modeled using 4-parametric logistic regression, which follows a sigmoidal distribution to represent the optical density range (40). Spearman's rank correlation was used to determine the relationship between two non-parametric continuous variables (41). Linear models were used to visualize the relationship between continuous values of relevant biomarkers (42). Locally estimated scatterplot smoothing (LOESS) models were used to visualize the trend of relevant biomarkers over days since symptom onset (43). LOESS models were implemented using a span = 1. The span was determined based on the best visualization that accounts for the low

sample size and large gaps between the sample days. Data were analyzed using R language version 4.1.1 within the RStudio (2021.09.0, Build 351) integrated development environment. Plots were visualized using the base R graphics and ggplot2 (v3.3.5) package. Statistical tests used in this study include ANOVA analysis with multiple comparisons test as well as t-tests, as indicated in the figure legends. Resultant *p*-values from the above statistical tests are displayed as ns, not significant ( $p \ge 0.05$ ) or with asterisks as follows: \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, or \*\*\*\*p < 0.0001. All statistics not indicated are not significant.

- 401
- 402

## 403 Acknowledgments

404 This study was supported by NIH grants, R01 AI24493 (E.H.) and R01 AI168003 (E.H.), and by 405 São Paulo Research Foundation-FAPESP (Project #2013/01690-0 to ECS and Scholarships

406 #2013/01702-9 and 2017/16627-3 to FTGS). SBB was supported in part as an Open Philanthropy

407 Awardee of the Life Sciences Research Foundation.

408

## 410 Figures Legends

411

412 Fig. 1. Development of quantitative YFV NS1 ELISA. (A) Sigmoidal standard curve of YFV 413 NS1 capture ELISA performed with YFJ19 mAb and thirteen different concentrations of 414 recombinant YFV NS1. (B) Comparison of standard curve of YFV NS1 diluted or not in normal 415 human serum (1:10). (C) Specificity of mAb YFJ19 by direct ELISA performed with NS1 (5 416 ug/mL) from 12 different flaviviruses as follows: YFV; dengue virus serotypes 1 (DENV1), 2 417 (DENV2), 3 (DENV2), and 4 (DENV4); Saint Louis encephalitis virus (SLEV); West Nile virus 418 (WNV); Zika virus (ZIKV); Wesselsbron virus (WBV); Usutu virus (USUV); Japanese 419 encephalitis virus (JEV); Tick-borne encephalitis virus (TBEV). (D) Cross-reactivity an anti-420 flavivirus NS1 mAb (2B7) by direct ELISA performed with NS1 (5 ug/mL) from the 12 different flaviviruses as in C. (E) Western blot analysis showing specificity of mAb YFJ19 for YFV NS1. 421 422 423 Fig. 2. YFV NS1 serum levels in severe and non-severe YF patients. (A) YFV NS1 levels were 424 determined using an in-house sandwich ELISA, as described in Materials and Methods. Studied 425 individuals were classified in three different groups as described in Materials and Methods: 1)

426 Severe YF (n=39); non-severe YF (n=16); controls (n=5): healthy individuals. (*B*) YFV NS1 levels 427 in survivors and deceased YFV-infected groups. Mean ranks of groups were compared by Mann-428 Whitney test (significance level of 0.05). (*C*) YFV NS1 serum levels in individuals with acute YF 429 according to days since symptom onset, visualized using a LOESS model.

430

431 Fig. 3. sSDC-1 levels in sera of individuals with acute YF and dengue. (A) The sSDC-1 levels 432 in sera were determined by the Human sSDC-1 ELISA Kit. Studied individuals were classified in 433 three different groups as described in Materials and Methods: 1) Severe YF (n=39); non-severe YF 434 (n=18); controls (n=11): healthy individuals. (B) sSDC-1 serum levels in survivors and deceased 435 YFV-infected groups. (C) Distribution and average (solid lines) of sSDC-1 serum levels in 436 individuals with acute YF according to days since symptoms onset, visualized using a LOESS 437 model. (D) sSDC-1 serum levels in individuals with acute DENV infection. Dengue no leak (n=7): 438 individuals with acute dengue who did not display plasma leakage; Dengue leak (n=7): individuals 439 with acute dengue who displayed plasma leakage; Controls (n=11): same healthy individuals 440 shown in panel A. Mean ranks of sSDC-1 levels of YF or dengue groups were compared by

Kruskal-Wallis + Dunn's multiple comparisons test. Median of sSDC-1 levels in deceased and
 survived patients were compared Mann Whitney test (significance level of 0.05).

443

444 Fig. 4. Relative TEER of human endothelial cells treated with acute YF human serum 445 samples and IFA of SDC-1 after NS1 treatment. (A) Confluent monolayers of human endothelial 446 cells cultured in Transwell inserts were treated or not with 10% serum from three different groups: 447 1) Severe YF (n=24); Non-severe YF (n=10); Controls (n=11): healthy individuals. YFV NS1 (10 448 ug/mL) was used as positive control. The transendothelial electrical resistance (TEER) was 449 measured from 2 to 10h post-treatment. Graph shows mean  $\pm$  SD of relative TEER for each 450 treatment group. (B) Area under the curve (AUC) calculation for the different treatments. Mean 451 values of AUC for each group were compared to untreated medium-only control group using one-452 way ANOVA + Tukey's test. (C, D) Human endothelial cell monolayers grown in gelatin-coated 453 coverslips were treated with (C) medium only or (D) 10 ug/mL of YFV NS1 for 3h. After fixation, 454 cell surface SDC-1 was stained in red and nuclei in blue. (E) Quantification of SDC-1 protein on 455 to the cells surface was expressed as mean fluorescence intensity (MFI) as shown in panels C and 456 D. NS1 treatment was compared to medium-only treatment by t-test. Asterisks indicate significant 457 difference with p < 0.05.

458

## 459 Fig. 5. Correlation analysis of clinical and laboratory data of study participants during acute

460 YF. (A) Correlation matrix analyzed by Spearman test using a linear model. Asterisks indicate 461 significant correlations (p<0.05, Spearman r>0.35). (B) Correlation between serum levels of YFV 462 NS1 and sSDC-1. (C) Correlation between serum levels of YFV NS1 and TEER AUC values. (D) 463 Correlation between serum levels of sSDC-1 and TEER AUC values. Abbreviations: TEER, 464 transendothelial electrical resistance; AUC, area under the curve; Hb, hemoglobin; Ht, hematocrit; 465 AST, aspartate transaminase; ALT, alanine aminotransferase; TPI/INR thrombin potential 466 index/international normalized ratio; aPTT, activated partial thromboplastin time; TB, total bilirubin; DB, direct bilirubin; IB, indirect bilirubin. 467

468

## 485 **References**

4	8	6
---	---	---

- M. U. Kraemer, *et al.*, Spread of yellow fever virus outbreak in Angola and the Democratic
   Republic of the Congo 2015–16: a modelling study. *Lancet Infect. Dis.* 17, 330–338 (2017).
- 489 2. E. G. Kallas, *et al.*, Predictors of mortality in patients with yellow fever: an observational
  490 cohort study. *Lancet Infect. Dis.* 19, 750–758 (2019).
- 491 3. C. L. Gardner, K. D. Ryman, Yellow fever: a reemerging threat. *Clin. Lab. Med.* 30, 237–260
  492 (2010).
- 493 4. D. R. Glasner, H. Puerta-Guardo, P. R. Beatty, E. Harris, The good, the bad, and the
  494 shocking: the multiple roles of dengue virus nonstructural protein 1 in protection and
  495 pathogenesis. *Annu. Rev. Virol.* 5, 227–253 (2018).
- 5. D. H. Libraty, *et al.*, High circulating levels of the dengue virus nonstructural protein NS1
  early in dengue illness correlate with the development of dengue hemorrhagic fever. *J. Infect. Dis.* 186, 1165–1168 (2002).
- 499 6. S. A. Paranavitane, *et al.*, Dengue NS1 antigen as a marker of severe clinical disease. *BMC*500 *Infect. Dis.* 14, 570 (2014).
- 501 7. H. T. L. Duyen, *et al.*, Kinetics of plasma viremia and soluble nonstructural protein 1
   502 concentrations in dengue: differential effects according to serotype and immune status. *J.* 503 *Infect. Dis.* 203, 1292–1300 (2011).
- H. Puerta-Guardo, *et al.*, Flavivirus NS1 Triggers Tissue-Specific Vascular Endothelial
   Dysfunction Reflecting Disease Tropism. *Cell Rep.* 26, 1598-1613.e8 (2019).
- 506 9. H. Puerta-Guardo, *et al.*, Flavivirus NS1 Triggers Tissue-Specific Disassembly of
  507 Intercellular Junctions Leading to Barrier Dysfunction and Vascular Leak in a GSK-3β508 Dependent Manner. *Pathogens* 11, 615 (2022).
- 509 10. P. Pan, *et al.*, DENV NS1 and MMP-9 cooperate to induce vascular leakage by altering
  510 endothelial cell adhesion and tight junction. *PLoS Pathog.* 17, e1008603 (2021).

511	11. A. W. Wessel, et al., Levels of circulating NS1 impact West Nile virus spread to the brain. J
512	<i>Virol.</i> <b>95</b> , e00844-21 (2021).

513	12. L. Hui, et al., Matrix metalloproteinase 9 facilitates Zika virus invasion of the testis by
514	modulating the integrity of the blood-testis barrier. PLoS Pathog. 16, e1008509 (2020).

- 515 13. C.-Y. Lin, *et al.*, High levels of serum hyaluronan is an early predictor of dengue warning
  516 signs and perturbs vascular integrity. *EBioMedicine* 48, 425–441 (2019).
- 517 14. D. A. Espinosa, *et al.*, Increased serum sialic acid is associated with morbidity and mortality
  518 in a murine model of dengue disease. *J. Gen. Virol.* 100, 1515–1522 (2019).

519 15. H. Puerta-Guardo, *et al.*, Zika Virus Nonstructural Protein 1 Disrupts Glycosaminoglycans
520 and Causes Permeability in Developing Human Placentas. *J. Infect. Dis.* 221, 313–324
521 (2020).

522 16. V. Mariappan, S. Adikari, L. Shanmugam, J. M. Easow, A. B. Pillai, Expression dynamics of
523 vascular endothelial markers: Endoglin and syndecan-1 in predicting dengue disease
524 outcome. *Transl. Res.* 232, 121–141 (2021).

525 17. H.-R. Chen, *et al.*, Macrophage migration inhibitory factor is critical for dengue NS1526 induced endothelial glycocalyx degradation and hyperpermeability. *PLoS Pathog.* 14,
527 e1007033 (2018).

18. T. H.-C. Tang, *et al.*, Increased serum hyaluronic acid and heparan sulfate in dengue fever:
association with plasma leakage and disease severity. *Sci. Rep.* 7, 1–9 (2017).

19. A. D. Theocharis, S. S. Skandalis, G. N. Tzanakakis, N. K. Karamanos, Proteoglycans in
health and disease: novel roles for proteoglycans in malignancy and their pharmacological
targeting. *FEBS J.* 277, 3904–3923 (2010).

20. L. Liu, M. Akkoyunlu, Circulating CD138 enhances disease progression by augmenting
autoreactive antibody production in a mouse model of systemic lupus erythematosus. *J. Biol. Chem.* 297, 101053 (2021).

536	21. T. Manon-Jensen, Y. Itoh, J. R. Couchman, Proteoglycans in health and disease: the multiple
537	roles of syndecan shedding. FEBS J. 277, 3876–3889 (2010).
538	22. K. Suzuki, et al., Serum syndecan-1 reflects organ dysfunction in critically ill patients. Sci.
539	<i>Rep.</i> <b>11</b> , 1–9 (2021).
540	23. R. Vollenberg, et al., Indications of persistent glycocalyx damage in convalescent COVID-19
541	patients: a prospective multicenter study and hypothesis. Viruses 13, 2324 (2021).
542	24. D. Zhang, et al., Syndecan-1, an indicator of endothelial glycocalyx degradation, predicts
543	outcome of patients admitted to an ICU with COVID-19. Mol. Med. 27, 1-12 (2021).
544	25. S. Suwarto, R. T. Sasmono, R. Sinto, E. Ibrahim, M. Suryamin, Association of Endothelial
545	Glycocalyx and Tight and Adherens Junctions With Severity of Plasma Leakage in Dengue
546	Infection. J. Infect. Dis. 215, 992–999 (2017).
547	26. F. Tramontini Gomes de Sousa Cardozo, et al., Serum from dengue virus-infected patients
548	with and without plasma leakage differentially affects endothelial cells barrier function in
549	vitro. PloS One 12, e0178820 (2017).
550	27. S. B. Biering, et al., Structural basis for antibody inhibition of flavivirus NS1-triggered
551	endothelial dysfunction. Science 371, 194–200 (2021).
552	28. S. Gaudette, D. Hughes, M. Boller, The endothelial glycocalyx: structure and function in
553	health and critical illness. J. Vet. Emerg. Crit. Care 30, 117-134 (2020).
554	29. P. K. Lam, et al., Visual and biochemical evidence of glycocalyx disruption in human dengue
555	infection, and association with plasma leakage severity. Front. Med. 7, 545813 (2020).
556	30. B. Buijsers, et al., Increased plasma heparanase activity and endothelial glycocalyx
557	degradation in dengue patients is associated with plasma leakage. Front. Immunol. 12,
558	Article number 759570 (2021).
559	31. A. Haynes III, et al., Syndecan 1 shedding contributes to Pseudomonas aeruginosa sepsis.
560	Infect. Immun. 73, 7914–7921 (2005).

561	32. H. Joensuu, et al., Soluble syndecan-1 and serum basic fibroblast growth factor are new
562	prognostic factors in lung cancer. Cancer Res. 62, 5210–5217 (2002).

- 33. Z. Malek-Hosseini, S. Jelodar, A. Talei, A. Ghaderi, M. Doroudchi, Elevated Syndecan-1
  levels in the sera of patients with breast cancer correlate with tumor size. *Breast Cancer* 24,
  742–747 (2017).
- 34. F. A. Olímpio, *et al.*, Endothelium Activation during Severe Yellow Fever Triggers an Intense
  Cytokine-Mediated Inflammatory Response in the Liver Parenchyma. *Pathog. Basel Switz.*11, 1–7 (2022).
- 35. A.-N. Pelletier, *et al.*, Yellow fever disease severity is driven by an acute cytokine storm
  modulated by an interplay between the human gut microbiome and the metabolome. *medRxiv*, 2021.09.25.21264125 (2021).
- 36. A. L. Bailey, *et al.*, Consumptive coagulopathy of severe yellow fever occurs independently
  of hepatocellular tropism and massive hepatic injury. *Proc. Natl. Acad. Sci.* 117, 32648–
  32656 (2020).
- 575 37. A. P. Rathore, A. L. St. John, Cross-reactive immunity among flaviviruses. *Front. Immunol.*576 11, 334 (2020).
- 38. M. G. Guzman, *et al.*, Multi-country evaluation of the sensitivity and specificity of two
  commercially-available NS1 ELISA assays for dengue diagnosis. *PLoS Negl. Trop. Dis.* 4,
  e811 (2010).
- 39. C. A. Schneider, W. S. Rasband, K. W. Eliceiri, NIH Image to ImageJ: 25 years of image
  analysis. *Nat. Methods* 9, 671–675 (2012).
- 40. C. Ritz, F. Baty, J. C. Streibig, D. Gerhard, Dose-response analysis using R. *PloS One* 10,
  e0146021 (2015).
- 584 41. W. J. Conover, *Practical nonparametric statistics* (John Wiley & Sons, 1999).
- 585 42. J. M. Chambers, A. Freeny, R. M. Heiberger, "Linear models" in Statistical Models, (J. M.

- 586 Chambers and T. J. Hastie, Wadsworth & Brooks/Cole., 1992).
- 43. W. S. Cleveland, E. Grosse, W. M. Shyu, "Local regression models" in Statistical Models, (J.
- 588 M. Chambers and T. J. Hastie, Wadsworth & Brooks/Cole., 1992).

	Control (n=11)	Non-severe (n=18)	Severe <sup>#</sup> (n=39)	<i>p</i> -value (Non-severe vs Severe)
Age (years)	38 (22 - 67)	39 (19 - 74)	42 (18 - 72)	ns <i>p</i> =0.9039
Gender (male) <sup>a</sup>	4 (36.36%)	16 (88.89%)	35 (89.74%)	ns <i>p</i> =0.9959
Days after symptom onset <sup>b</sup>	-	9 (6 - 24)	7 (3 - 20)	* <i>p</i> =0.0245
Hospitalization <sup>a</sup>	-	11 (61.11%)	31 (79.49%)	ns <i>p</i> =0.1975
Viral load (genomic RNA copies/mL)	-	$1.04 \ge 10^3$ (3 - 2.50 \empty 10^4)	$2.03 \text{ x } 10^5 \\ (7 - 2.22 \text{ x } 10^8)$	**** p=0.0001
Leukocyte count <sup>c</sup>	nd	3.72 (1.35 - 6.78)	4.22 (1.44 - 17.09)	ns <i>p</i> =0.1782
Lymphocyte count <sup>c,d</sup>	nd	1.06 (0.26 – 2.14)	0.80 (0.21 – 2.19)	ns <i>p</i> =0.1119
Neutrophil count <sup>c</sup>	nd	1.75 (0.38 - 3.79)	2.98 (0.99 - 14.88)	** <i>p</i> =0.0061
Platelet count <sup>c,d</sup>	nd	89.00 (43.00 - 328.00)	67.00 (17.00 - 361)	ns <i>p</i> =0.1005
Hemoglobin (Hb, g/dL) <sup>d</sup>	nd	13.90 (7.20 - 16.50)	13.70 (6.40 - 18.20)	ns <i>p</i> =0.5454
Hematocrit (Ht, %) <sup>d</sup>	nd	40.85 (21.30 - 48.30)	38.95 (18.90 - 52.40)	ns <i>p</i> =0.3814
Aspartate transaminase (AST, U/L)	nd	521.5 (40 - 2510)	3736 (138 - 21721)	***p=0.0002
Alanine aminotransferase <sup>e</sup> (ALT, U/L)	nd	753 (42 - 2677)	2232 (59 - 8822)	** <i>p</i> =0.0060
Creatinine <sup>d</sup> (mg/dL)	nd	0.97 (0.44 - 1.52)	2.98 (0.65 - 10.50)	***p=0.0004
Fibrinogen <sup>g</sup> (mg/dL)	nd	184 (96 - 309)	138 (52 - 560)	ns <i>p</i> =0.2217
PT/INR <sup>d</sup>	nd	1.06 (0.94 - 1.78)	1.30 (0.95 - 3.51)	**** p=0.0001
aTTP <sup>f</sup> (s)	nd	30.90 (23.90 - 39.50)	38.85 (21.70 - 200)	** <i>p</i> =0.0012
Total bilirubin (TB, mg/dL) <sup>d</sup>	nd	1.04 (0.28 - 6.00)	4.72 (0.11 – 30.96)	** <i>p</i> =0.0025
Direct bilirubin (DB, mg/dL) <sup>d</sup>	nd	0.92 (0.16 - 5.88)	4.10 (0.15 – 27.16)	** <i>p</i> =0.0040
Indirect bilirubin (IB, mg/dL)	nd	0.15 (0.01 - 0.50)	0.62 (0.06 - 7.45)	* <i>p</i> =0.0124
Death <sup>a</sup>	-	0 (0%)	17 (42.50 %)	*** <i>p</i> =0.0006

Table 1: Demographic, clinical, and laboratory data of study participants

Data are shown as median (range). Groups were compared by Mann-Whitney (two groups) or Kruskal-Wallis (three groups) test.

<sup>a</sup> Gender, hospitalization, and death are reported as number of patients per group (percentage of total within each group).

<sup>b</sup>All the samples were collected upon hospital admission, and the days after symptom onset was determined based on patient report at admission.

<sup>c</sup> Leukocyte, lymphocyte, neutrophil, and platelet count are shown as number x 10<sup>3</sup>/mm<sup>3</sup> of blood.

<sup>d</sup> Data missing for one patient.

<sup>e</sup> Data missing for two patients.

<sup>f</sup>Data missing for six patients.

<sup>g</sup> Data missing for nine patients.

\* significant *p*-value.

Abbreviations: nd, not determined; ns, not significant; PT/INR: Prothrombin Time/International Normalized Ratio; aTTP, Activated Partial Thromboplastin Clotting Time.

<sup>#</sup>Liver transplant was required for one patient from the severe group.









